FLT3 and acute myeloid leukemia: To evaluate the effect of clustering on a large population of patients, we selected 210 patient samples (Table S1) from the larger Beat AML cohort11,12 based on the availability of samples with informed consent for research purposes and with an emphasis on FLT3-ITD mutations, given the advent of multiple new therapeutics targeting FLT3 mutations.